← FDMT
FDMT— 4D Molecular Therapeutics, Inc.
MaterialsBiological Products, (No Diagnostic Substances)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Collaboration and license revenue | $85.2M+230194.6% | $37K-99.8% | $20.7M+562.3% | $3.1M-82.7% | $18.0M+35.0% | $13.4M |
| Research and development (includes $1,322 and $1,005 for the years ended December 31, 2025 and 2024, respectively, attributable to related parties) | $195.7M+38.5% | $141.3M+45.5% | $97.1M+21.0% | $80.3M+30.8% | $61.4M+15.7% | $53.0M |
| General and administrative | $49.1M+5.3% | $46.6M+27.6% | $36.5M+10.9% | $32.9M+17.5% | $28.0M+62.5% | $17.2M |
| Total operating expenses | $244.8M+30.3% | $187.9M+40.6% | $133.6M+18.1% | $113.2M+26.6% | $89.4M+27.2% | $70.3M |
| Loss from operations | -$159.5M+15.1% | -$187.8M-66.4% | -$112.9M-2.6% | -$110.0M-54.3% | -$71.3M-25.9% | -$56.7M |
| Interest income | $19.5M-28.0% | $27.1M+121.5% | $12.2M+374.6% | $2.6M+1778.1% | $137K-9.9% | $152K |
| Other expense, net | -$37K+51.9% | -$77K+57.5% | -$181K-417.1% | -$35K+71.1% | -$121K+33.1% | -$181K |
| Total other income, net | $19.4M-27.9% | $27.0M+124.2% | $12.0M+374.0% | $2.5M+15762.5% | $16K+155.2% | -$29K |
| Net loss | -$140.1M+12.9% | -$160.9M-59.5% | -$100.8M+6.2% | -$107.5M-50.7% | -$71.3M-25.8% | -$56.7M |
| Net loss per share, basic | -$2K+18.8% | -$3K-15.5% | -$3K+22.3% | -$3K-29.2% | -$3K | — |
| Net loss per share, diluted | -$2K+18.8% | -$3K-15.5% | -$3K+22.3% | -$3K-29.2% | -$3K | — |
| Weighted-average shares outstanding used in computing net loss per share, basic | $57.93B+7.4% | $53.94B+37.9% | $39.13B+21.0% | $32.35B+16.7% | $27.73B | — |
| Weighted-average shares outstanding used in computing net loss per share, diluted | $57.93B+7.4% | $53.94B+37.9% | $39.13B+21.0% | $32.35B+16.7% | $27.73B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.